229. 肺胞蛋白症(自己免疫性又は先天性) Autoimmune pulmonary alveolar proteinosis Clinical trials / Disease details
臨床試験数 : 44 / 薬物数 : 22 - (DrugBank : 7) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 14
Showing 1 to 10 of 27 diseases
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2020-001263-85-ES (EUCTR) | 25/04/2022 | 02/02/2022 | A clinical trial where patients with the lung disease autoimmune pulmonary alveolar proteinosis will be given the drug molgramostim nebulizer solution by inhalation. A clinical trial where patients with the lung disease autoimmune pulmonary alveolar proteinosis will ... | A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP). - IMPALA-2 A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostimnebu ... | Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 21.1;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 21.1;Level: LLT;Classification code ... | Product Name: Molgramostim 300 µg nebulizer solution INN or Proposed INN: Molgramostim | Savara ApS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 160 | Phase 3 | United States;Portugal;Greece;Spain;Ireland;Turkey;Russian Federation;United Kingdom;Italy;France;Canada;Belgium;Poland;Romania;Australia;Germany;Netherlands;Japan;Korea, Republic of United States;Portugal;Greece;Spain;Ireland;Turkey;Russian Federation;United Kingdom;Italy;France;Ca ... | ||
2 | EUCTR2020-001263-85-NL (EUCTR) | 19/07/2021 | 08/10/2020 | A clinical trial where patients with the lung disease autoimmunePulmonary Alveolar Proteinosis will be given the drug molgramostim nebulizer solution byinhalation. A clinical trial where patients with the lung disease autoimmunePulmonary Alveolar Proteinosis will ... | A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP). - IMPALA-2 A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostimnebu ... | Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 21.1;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 21.1;Level: LLT;Classification code ... | Product Name: Molgramostim 300 µg nebulizer solution INN or Proposed INN: Molgramostim | Savara ApS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 160 | Phase 3 | United States;Ireland;Turkey;United Kingdom;Italy;France;Canada;Belgium;Poland;Romania;Netherlands;Germany;Japan;Korea, Republic of United States;Ireland;Turkey;United Kingdom;Italy;France;Canada;Belgium;Poland;Romania;Netherlands;G ... | ||
3 | NCT04544293 (ClinicalTrials.gov) | May 10, 2021 | 3/9/2020 | Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Clinical Trial of Inhaled MolgramostimNebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosi ... | A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled MolgramostimNebu ... | Autoimmune Pulmonary Alveolar Proteinosis | Drug: Molgramostim;Drug: Placebo | Savara Inc. | NULL | Recruiting | 18 Years | N/A | All | 160 | Phase 3 | United States;Australia;Belgium;Canada;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Turkey;United Kingdom;Russian Federation United States;Australia;Belgium;Canada;France;Germany;Greece;Ireland;Italy;Japan;Korea, Republic of; ... |
4 | EUCTR2020-001263-85-RO (EUCTR) | 11/03/2021 | 19/05/2022 | A clinical trial where patients with the lung disease autoimmunePulmonary Alveolar Proteinosis will be given the drug molgramostim nebulizer solution byinhalation. A clinical trial where patients with the lung disease autoimmunePulmonary Alveolar Proteinosis will ... | A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP). - IMPALA-2 A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostimnebu ... | Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 21.1;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 21.1;Level: LLT;Classification code ... | Product Name: Molgramostim 300 µg nebulizer solution INN or Proposed INN: Molgramostim | Savara ApS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 160 | Phase 3 | United States;Spain;Ireland;Turkey;United Kingdom;Italy;France;Canada;Poland;Belgium;Romania;Netherlands;Germany;Japan;Korea, Republic of United States;Spain;Ireland;Turkey;United Kingdom;Italy;France;Canada;Poland;Belgium;Romania;Netherl ... | ||
5 | EUCTR2020-001263-85-BE (EUCTR) | 08/03/2021 | 04/12/2020 | A clinical trial where patients with the lung disease autoimmunePulmonary Alveolar Proteinosis will be given the drug molgramostim nebulizer solution byinhalation. A clinical trial where patients with the lung disease autoimmunePulmonary Alveolar Proteinosis will ... | A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP). - IMPALA-2 A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostimnebu ... | Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 21.1;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 21.1;Level: LLT;Classification code ... | Product Name: Molgramostim 300 µg nebulizer solution INN or Proposed INN: Molgramostim | Savara ApS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 160 | Phase 3 | United States;Ireland;Turkey;United Kingdom;Italy;France;Canada;Belgium;Poland;Romania;Germany;Netherlands;Japan;Korea, Republic of United States;Ireland;Turkey;United Kingdom;Italy;France;Canada;Belgium;Poland;Romania;Germany;Nethe ... | ||
6 | EUCTR2020-001263-85-IE (EUCTR) | 08/02/2021 | 08/10/2020 | A clinical trial where patients with the lung disease autoimmunePulmonary Alveolar Proteinosis will be given the drug molgramostim nebulizer solution by inhalation. A clinical trial where patients with the lung disease autoimmunePulmonary Alveolar Proteinosis will ... | A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP). - IMPALA-2 A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostimnebu ... | Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 21.1;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 21.1;Level: LLT;Classification code ... | Product Name: Molgramostim 300 µg nebulizer solution INN or Proposed INN: Molgramostim | Savara ApS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 160 | Phase 3 | United States;Ireland;Turkey;Italy;United Kingdom;France;Canada;Belgium;Poland;Romania;Germany;Netherlands;Japan;Korea, Republic of United States;Ireland;Turkey;Italy;United Kingdom;France;Canada;Belgium;Poland;Romania;Germany;Nethe ... | ||
7 | EUCTR2020-001263-85-DE (EUCTR) | 27/01/2021 | 16/10/2020 | A clinical trial where patients with the lung disease autoimmunePulmonary Alveolar Proteinosis will be given the drug molgramostim nebulizer solution by inhalation. A clinical trial where patients with the lung disease autoimmunePulmonary Alveolar Proteinosis will ... | A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP). - IMPALA-2 A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostimnebu ... | Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 21.1;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 21.1;Level: LLT;Classification code ... | Product Name: Molgramostim 300 µg nebulizer solution INN or Proposed INN: Molgramostim | Savara ApS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 160 | Phase 3 | Portugal;United States;Greece;Spain;Ireland;Turkey;United Kingdom;Italy;France;Canada;Belgium;Poland;Romania;Australia;Germany;Netherlands;Japan;Korea, Republic of Portugal;United States;Greece;Spain;Ireland;Turkey;United Kingdom;Italy;France;Canada;Belgium;Poland ... | ||
8 | EUCTR2020-001263-85-PL (EUCTR) | 16/12/2020 | 19/11/2020 | A clinical trial where patients with the lung disease autoimmunePulmonary Alveolar Proteinosis will be given the drug molgramostim nebulizer solution by inhalation. A clinical trial where patients with the lung disease autoimmunePulmonary Alveolar Proteinosis will ... | A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP). - IMPALA-2 A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostimnebu ... | Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 21.1;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 21.1;Level: LLT;Classification code ... | Product Name: Molgramostim 300 µg nebulizer solution INN or Proposed INN: Molgramostim | Savara ApS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 160 | Phase 3 | Portugal;United States;Greece;Spain;Ireland;Turkey;United Kingdom;Italy;France;Canada;Belgium;Poland;Romania;Australia;Netherlands;Germany;Japan;Korea, Republic of Portugal;United States;Greece;Spain;Ireland;Turkey;United Kingdom;Italy;France;Canada;Belgium;Poland ... | ||
9 | EUCTR2020-001263-85-IT (EUCTR) | 18/11/2020 | 24/05/2021 | A clinical trial where patients with the lung disease autoimmune Pulmonary Alveolar Proteinosis will be given the drug molgramostim nebulizer solution by inhalation. A clinical trial where patients with the lung disease autoimmune Pulmonary Alveolar Proteinosis will ... | A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP) - IMPALA-2 A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostimnebu ... | Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 21.1;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 21.1;Level: LLT;Classification code ... | Product Name: Molgramostim 300 µg nebulizer solution Product Code: [na] INN or Proposed INN: 00201600 | SAVARA APS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 160 | Phase 3 | United States;Korea, Democratic People's Republic of;Ireland;Turkey;United Kingdom;Italy;France;Canada;Belgium;Poland;Romania;Germany;Netherlands;Japan;Korea, Republic of United States;Korea, Democratic People's Republic of;Ireland;Turkey;United Kingdom;Italy;France;Cana ... | ||
10 | EUCTR2017-004078-32-IT (EUCTR) | 16/05/2019 | 07/01/2019 | Clinical trial in patients with the lung disease, autoimmune pulmonary alveolar proteinosis, to assess continued treatment with molgramostim by inhalation Clinical trial in patients with the lung disease, autoimmune pulmonary alveolar proteinosis, to asse ... | AN OPEN-LABEL, NON-CONTROLLED, MULTICENTRE CLINICAL TRIAL OF INHALED MOLGRAMOSTIM IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS PATIENTS - IMPALA-EX AN OPEN-LABEL, NON-CONTROLLED, MULTICENTRE CLINICAL TRIAL OF INHALED MOLGRAMOSTIMIN AUTOIMMUNE PULMO ... | Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 20.0;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] Autoimmune Pulmonary Alveolar Proteinosis (aPAP) MedDRA version: 20.0;Level: LLT;Classification code ... | Product Name: Molgramostim Nebuliser solution 300 mcg INN or Proposed INN: MOLGRAMOSTIM | Savara ApS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 90 | Phase 3 | Netherlands;France;Greece;Denmark;Russian Federation;Israel;Germany;United Kingdom;Italy |